When was Avenzo Therapeutics founded?

Avenzo Therapeutics was founded in 2022 and raised its 1st funding round within a year of its incorporation.

Where is Avenzo Therapeutics located?

Avenzo Therapeutics is headquartered in San Diego, United States.

Who is the current CEO of Avenzo Therapeutics?

Athena Countouriotis of Avenzo Therapeutics. They have also founded 1 company.

How many employees does Avenzo Therapeutics have?

As of Jul 31, 2026, the latest employee count at Avenzo Therapeutics is 61.

Is Avenzo Therapeutics a funded company?

Avenzo Therapeutics is a funded company, having raised a total of $446M across 3 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Sep 14, 2022.

When was the latest funding round of Avenzo Therapeutics?

Avenzo Therapeutics' latest funding was a $***** Series B round on Aug 22, 2025, with participation from 14 investors.

Where does Avenzo Therapeutics rank among its competitors?

Avenzo Therapeutics ranks 240th amongst 3301 active competitors, of which 1117 are funded. It stands 3rd in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of Avenzo Therapeutics?

Avenzo Therapeutics' top competitors include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

Avenzo Therapeutics - 2026 Company Profile, Team, Funding & Competitors

Avenzo Therapeutics is a series B company based in San Diego (United States), founded in 2022 by Athena Countouriotis and Mohammad Hirmand. It operates as a Developer of therapeutics for cancer treatment. Avenzo Therapeutics has raised $446M in funding from investors like New Enterprise Associates, Orbimed and Sofinnova Investments. The company has 3301 active competitors, including 1117 funded and 778 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Sana Biotechnology.

Company Details

Developer of therapeutics for cancer treatment. It offers a pipeline of oncology therapies which include AVZO-021 is a selective inhibitor of CDK2 for advanced solid tumors and HR+/HER2-negative metastatic breast cancer, ARTS-023 is a selective CDK4 inhibitor for HR+ breast cancer, AVZO-1418 is a BsADC targeting EGFR and HER3 for non-small cell lung cancer, and VAC-103 BsADC targeting Nectin4 and TROP2 for urothelial and breast cancers.

Key Metrics

Founded Year

2022

Location

San Diego, United States

Stage

Series B

Total Funding

$446M in 3 rounds

Latest Funding Round

Series B, Aug 22, 2025, $*****

Investors

New Enterprise Associates & 16 more

Ranked

240^th among 3301 active competitors

Employee Count

61 as on Jul 31, 2026

Similar Companies

Jazz Pharmaceuticals & 2983 more

View Avenzo Therapeutics' full profile

Avenzo Therapeutics is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
AVENZO THERAPEUTICS INC CIN: 883737798 , United States, Active	Apr 19, 2023	-	34 (As on Dec 31, 2024)	-

Avenzo Therapeutics has raised a total funding of $446M over 3 rounds. Its first funding round was on Sep 14, 2022. Its latest funding round was a Series B round on Aug 22, 2025 for $*****. 14 investors participated in its latest round. Avenzo Therapeutics has 17 institutional investors.

Here is the list of recent funding rounds of Avenzo Therapeutics:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Aug 22, 2025	1693789	Series B	5399688	9910757	9523118	9514805
Nov 18, 2024	9138620	Series A	6207016	1927825	2256314	Orbimed & 12 more
Sep 14, 2022	1401776	Series A	2379029	6960141	New Enterprise Associates & 3 more	INCE Capital & 3 more

Access funding benchmarks and valuations. Sign up today!

View details of Avenzo Therapeutics's funding rounds and investors

The founders of Avenzo Therapeutics are Athena Countouriotis and Mohammad Hirmand. Athena Countouriotis is the CEO of Avenzo Therapeutics.

Here are the details of Avenzo Therapeutics' key team members:

Athena Countouriotis: Co-Founder & CEO of Avenzo Therapeutics.
Mohammad Hirmand: Co-Founder & Chief Medical Officer of Avenzo Therapeutics.
Contact Info: 1 email address

View details of Avenzo Therapeutics's Founder profiles and Board Members

Avenzo Therapeutics' employee count trend

Avenzo Therapeutics has 61 employees as of Jul 26. Here is Avenzo Therapeutics's employee count trend over the years:

Employee count trend for Avenzo Therapeutics

Uncover Avenzo Therapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Avenzo Therapeutics include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of Avenzo Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	80/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, F-Prime Capital & 18 others	73/100
4th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
5th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, New Enterprise Associates ... & 30 others	72/100
6th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
7th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
8th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	71/100
9th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	71/100
10th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
240th	Avenzo Therapeutics 2022, San Diego (United States), Series B	Developer of therapeutics for cancer treatment	$446M	Foresite Capital, Deep Track Capital & 15 others	58/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on Avenzo Therapeutics's competitors? Click here to see the top ones

Avenzo Therapeutics has made no investments or acquisitions yet.

Here is the latest report on Avenzo Therapeutics's sector:

Free

Oncology - Sector Report

Edition: July, 2026 (74 Pages)

View all reports related to Avenzo Therapeutics

Media has covered Avenzo Therapeutics for a total of 12 events in the last 1 year, 5 of them have been about company updates and 3 about people movement.